PT-141 (Bremelanotide) MMA / Combat Sports Protocol: Dosing, Timing, and Evidence

The direct answer

PT-141 is FDA-approved for one narrow indication, HSDD in premenopausal women, based on the Vyleesi new drug application reviewed in 2019. Every use discussed on this page, including recovery after sparring, neuroinflammation control, and soft-tissue healing in combat-sports athletes, is off-label and has not been evaluated in a human clinical trial for that purpose. Animal studies of MC4R agonists report reduced inflammatory cytokines and improved outcomes after experimental brain injury, which is biologically plausible support for the neuroprotection rationale some practitioners cite, but plausibility in rodents is not evidence of benefit in fighters. Current concussion-management guidance does not endorse any pharmacological agent for acute concussion care, and that has not changed because of melanocortin research.

What PT-141 is, and what it is not

PT-141 is the research and compounding name for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It acts on melanocortin receptors, most relevant here is MC4R, which is expressed in hypothalamic and brainstem regions involved in autonomic tone, appetite, and inflammatory signaling. The FDA-approved product, Vyleesi, is a 1.75 mg subcutaneous auto-injector approved in 2019 for HSDD.

Compounded PT-141 sold outside that approved product is a different regulatory category. The FDA has stated that compounded versions of approved drugs require a valid patient-specific prescription and are not subject to the same manufacturing review as the approved product (compounding of approved drugs generally requires a valid patient-specific prescription under FDA policy; verify current requirements with a pharmacist or the FDA directly before relying on this).

This is not an anabolic or muscle-building peptide. The rationale athletes and coaches cite is recovery quality after repetitive impact, not hypertrophy or strength.

Evidence hierarchy: what actually supports the combat-sports use case

No randomized controlled trial has tested PT-141 in human combat-sports athletes for recovery, neuroprotection, or soft-tissue repair. Applying a standard evidence hierarchy (regulatory label, then guidelines, then trials, then case-series) to this specific use case looks like this:

1. FDA label and pharmacokinetic data (Vyleesi, HSDD population). The approved product's pharmacokinetic and adverse-event data come from trials in premenopausal women with HSDD, not athletes. Reported effects in that population included nausea in a large minority of subjects and a transient rise in blood pressure in the hours after injection (per the FDA-approved product labeling for Vyleesi). These figures describe a different population and should not be assumed to transfer unchanged to a young, generally healthy combat-sports population; an editor or clinician should confirm the exact percentages against the current label before they are quoted as fact on this page.
2. Concussion-management guidelines. Existing sports-neurology concussion guidelines do not endorse any pharmacological agent, melanocortin or otherwise, for acute concussion management. That absence of endorsement is itself a meaningful data point: it means no agent, including PT-141, has cleared the bar these guideline bodies require.
3. Animal and in-vitro studies. Rodent studies of MC4R agonists (bremelanotide and structurally related compounds such as MTII) have reported reduced pro-inflammatory cytokines, reduced lesion volume, and improved behavioral outcomes after experimental traumatic brain injury or stroke. Separate in-vitro work on MC1R has reported effects on keratinocyte and fibroblast activity relevant to wound healing. These are legitimate preclinical findings, but the specific papers and effect sizes cited in older drafts of this article could not be independently verified for this revision, so exact percentages and journal citations have been removed rather than restated with unverified numbers. An editor with primary-literature access should re-attach specific citations before publication.
4. Practitioner case-series. Sports-medicine peptide clinics have reported observational experience with PT-141 in fighters, including subjective sleep-quality improvement and reduced self-reported post-sparring headache duration. This is Level IV evidence by standard grading (expert opinion and case-series, per the Oxford Centre for Evidence-Based Medicine framework, cebm.ox.ac.uk). Case-series data cannot rule out placebo effect, regression to the mean, or confounding from concurrent recovery interventions.

Evidence-boundary statement: it is established that PT-141 is FDA-approved for HSDD and that MC4R agonism affects inflammatory signaling in animal injury models. It is plausible but unproven that this translates into meaningful neuroprotective or recovery benefit in human combat-sports athletes. It is not established that PT-141 treats, prevents, or accelerates recovery from concussion, soft-tissue injury, or any combat-sports-specific condition in humans.

How off-label combat-sports protocols are typically described

The following reflects what practitioner case-series and off-label prescribing patterns commonly describe, not an individualized recommendation. Any specific dose, frequency, or cycle length for a given athlete should be set by a licensed prescriber who has reviewed that athlete's cardiovascular status, concussion history, medication list, and competition calendar.

• Reported starting doses in the low range (around 0.5 mg subcutaneous) are commonly used as a tolerability test before any increase.
• Reported maintenance doses described in practice generally stay below the FDA-approved 1.75 mg HSDD dose, in part because nausea is dose-related and can impair next-day training.
• Reported frequency is typically two to three injections per week on hard-training days rather than daily use, since continuous receptor stimulation with a short-half-life peptide raises theoretical concerns about receptor desensitization that have not been formally studied for bremelanotide specifically.
• Reported cycle length in practitioner consensus is commonly four to eight weeks with a washout period, but there is no long-term human safety data for repeated cycling, so this boundary is a caution-based convention rather than a trial-derived finding.
• Fight-week practice commonly involves stopping well before competition to avoid any residual blood-pressure variability or antidoping testing complications, discussed further below.

None of the above should be read as dosing instructions. It describes what is reported in the off-label ecosystem so that an athlete and their physician can evaluate it critically, not so a reader can self-administer.

Clinician-discussion and monitoring framework

The table below is an original framework for structuring a conversation between an athlete and a prescribing clinician about off-label PT-141 use. It separates what the FDA label actually supports from what would require individualized clinical judgment, and it defines checkpoints and stop conditions. It is not a substitute for an individualized medical evaluation.

A note on the neuroprotection question specifically: because no phase II or III human trial exists, a clinician discussing PT-141 for post-impact recovery should disclose that this use is investigational, explain that the supporting data come from animal models and uncontrolled case reports, and document that the athlete understands this before proceeding. That is a matter of standard informed-consent practice for off-label prescribing generally, not a specific claim attributed to any single guideline document.

Anti-doping and regulatory status (dated)

As of the World Anti-Doping Agency's 2025 Prohibited List, bremelanotide is not listed as a prohibited substance. Athletes should check the current list directly, since WADA updates it annually each January and status can change (wada-ama.org). Separately, individual jurisdictions such as U.S. state athletic commissions can maintain their own testing panels that differ from WADA's list. Verifying with the specific commission before a tested competition is the only reliable approach, and any timeline for stopping use before competition should come from that commission's guidance plus the prescriber's judgment about individual clearance, not from a fixed rule stated here.

Compounded PT-141 exists in a different regulatory position than the FDA-approved Vyleesi product. The FDA's compounding guidance states that compounded versions of approved drugs require a valid, patient-specific prescription (per general FDA compounding policy). Sourcing, purity, and dosing accuracy of compounded peptide products are not subject to the same review as the approved drug, which is a separate risk from the pharmacological risk of bremelanotide itself.

Contraindications and situations requiring urgent care

Based on the FDA label for the approved indication and general clinical reasoning, the following are reasons to avoid or pause off-label PT-141 use pending physician input:

• Uncontrolled hypertension or known structural cardiovascular disease, given the drug's transient pressor effect
• Pregnancy: bremelanotide carries an FDA pregnancy contraindication based on animal reproductive toxicity data; this is not relevant to most combat-sports use cases but should be ruled out where applicable
• An active, unresolved concussion or return-to-play protocol, where introducing an unstudied agent adds a confound to recovery monitoring
• Concurrent naltrexone or other opioid antagonist use, which may alter the expected receptor signaling and adverse-event profile
• Any new chest pain, palpitations, sustained blood pressure elevation, or severe unresponsive nausea after a dose warrants stopping the peptide and contacting a physician promptly; these are not situations to manage by adjusting the next dose independently

What this page cannot tell you

This page cannot state a validated dose, frequency, or cycle length for a specific athlete, because no clinical trial has established one for this indication. It cannot confirm that PT-141 improves concussion recovery, headache burden, or soft-tissue healing in humans, because that trial does not exist. It can describe what is FDA-approved, what animal and case-series evidence exists, and where the boundaries of that evidence sit, so that a reader and their physician can have an informed conversation rather than relying on a confident-sounding but unsupported protocol.